ELUTIA INC.
corporate_fare Company Profile
ELUTIA INC. (NASDAQ:ELUT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for ELUT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-21, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ELUT spans 8-K, 10-Q, DEF 14A, 10-K.
Recent high-impact activity:
- Elutia Closes SimpliDerm Sale, Receives $7.7M Cash to Fund NXT-41x Launch
- Elutia Faces Nasdaq Delisting, Secures $15M Loan, and Divests SimpliDerm
- Elutia Posts Q2 Loss but Says Funding Is in Place Through NXT-41x Launch Without Equity Offering
- Elutia Secures $15M Loan to Fund NXT-41x Launch in $1.5B Market
- Elutia Faces Nasdaq Delisting After Stock Sinks Below $1.00
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 8,223 shares in ELUT as of the September 15, 2026 settlement, a 51.5% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 23.5% of ELUT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ELUT, detected from its recent SEC filings · based on capital-structure filings through 2026-04-22.
Proposed Expansion of Equity Incentive Plan · Significant Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →